Fig. 4.

Characterization of the targeted KEAP1 degradation capacity of compound 14. (A) HEK293T cells were pre-treated with DMSO, 10 μM of thalidomide (TOM), 10 μM of proteasome inhibitor MG132, or 1 μM of inhibitor 2 for 1 h. Cells were then treated and incubated with 14 for 5 h. (B) HEK293T cells were treated with DMSO vehicle control or compound 14 at the indicated concentrations for 24 h. Immunoblots are representative of 3 independent repeats. Repeats are shown in Figs. S4 and S5.